Table 1. Summary of results for association of rs4458204_A with risk of dying from breast cancer.
| Patients | n | Breast cancer-specific deaths | Per-allele HR (95% CI) * | P -value |
|---|---|---|---|---|
| Discovery | ||||
| ER-negative | 2,218 | 332 | 1.83 (1.47–2.27) | 4.68 × 10−8 |
| ER-negative not treated with chemotherapy | 411 | 53 | 1.39 (0.69–2.81) | 0.36 |
| ER-negative and treated with chemotherapy | 1,804 | 279 | 1.96 (1.55–2.47) | 1.60 × 10−8 |
| I2=0%; Phet=0.84 | ||||
| Replication | ||||
| ER-negative and treated with chemotherapy | ||||
| iCOGS Asian studies | 522 | 53 | 1.97 (0.94–4.17) | 0.07 |
| POSH | 315 | 108 | 1.41 (0.95–2.09) | 0.08 |
| Combined replication | ||||
| ER-negative and treated with chemotherapy | 837 | 161 | 1.52 (1.07–2.15) | 0.02 |
| I2=0%; Phet=0.44 | ||||
| Combined overall | ||||
| ER-negative and treated with chemotherapy | 2641 | 440 | 1.81 (1.49–2.19) | 1.90 × 10−9 |
| I2=1.4%; Phet=0.36 | ||||
CI, confidence interval; COGS, Collaborative Oncological Gene-environment Study; ER, oestrogen receptor; HR, hazard ratio; I2, I2 metric; Phet, P for heterogeneity; POSH, Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer.
*Fifteen-year breast cancer-specific survival, delayed-entry Cox proportional hazards model stratified by study and adjusted for population stratification, age at diagnosis, tumour size, presence of distant metastasis, lymph node status, tumour grade as well as surgery, chemotherapy, hormone therapy and radiotherapy.